MARIBAVIR AS ANTI-CMV TREATMENT IN REFRACTORY OR RESISTANT DISEASES IN A NON-TRANSPLANT SETTING (SIE 2025) - Oct 27, 2025 - Abstract #SP05; "First CMV reactivation was observed during induction with RDHAX; it was resolved with Valganciclovir...Foscarnet was started as second-line, obtaining virus clearance...After two weeks, we obtained a complete response, permitting us to start a bridge therapy to HSCT with Glofitamab. After Maribavir stop, it was also started a prophylactic therapy with Letermovir...Ganciclovir therapy was started and despite a clinical improvement, after 3 weeks CMV was still detectable...That permitted us to start the anti-HCL therapy with 2-CDA, after which the patient expe- rienced pancytopenia with two bacterial complications, but no CMV positivity was anymore detected even after Maribavir stop...In both cases we obtained a long lasting virus clearance after two weeks of treatment. Further evaluations are needed, but from these first datas we can speculate about the possibility to extend the use of Maribavir also in immunocompromised not-transplanted patients."
Bone Marrow Transplantation • Cytomegalovirus Infection • Diffuse Large B Cell Lymphoma • Genetic Disorders • Hairy Cell Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Ocular Inflammation • Retinal Disorders • Transplantation • Uveitis
|
|
U. Pizzano; G. De Cicco; D. Schiavo; E. Scarpa; M. Stanzani
|